Hoth Therapeutics Inc has a consensus price target of $7.63, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., EF Hutton, and EF Hutton on February 5, 2024, September 14, 2023, and August 23, 2023. With an average price target of $8.5 between HC Wainwright & Co., EF Hutton, and EF Hutton, there's an implied 470.47% upside for Hoth Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/05/2024 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 168.46% | HC Wainwright & Co. | Raghuram Selvaraju | → $4 | Initiates | → Buy | Get Alert |
09/14/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 403.36% | EF Hutton | Elemer Piros | $12 → $7.5 | Maintains | Buy | Get Alert |
08/23/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 839.6% | EF Hutton | Elemer Piros | → $14 | Assumes | → Buy | Get Alert |
06/20/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 235.57% | Benchmark | Bruce Jackson | → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
06/01/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 839.6% | EF Hutton | Elemer Piros | → $14 | Assumes | → Buy | Get Alert |
04/27/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 839.6% | EF Hutton | Constantine Davides | → $14 | Reiterates | → Buy | Get Alert |
04/10/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 235.57% | Benchmark | Bruce Jackson | → $5 | Reiterates | → Speculative Buy | Get Alert |
04/03/2023 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 839.6% | EF Hutton | Constantine Davides | $33 → $14 | Maintains | Buy | Get Alert |
12/30/2022 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 2114.77% | EF Hutton | Constantine Davides | $45 → $33 | Maintains | Buy | Get Alert |
03/31/2022 | HOTH | Buy Now | Hoth Therapeutics | $1.49 | 67.79% | EF Hutton | Constantine Davides | $68.75 → $62.5 | Maintains | Buy | Get Alert |
The latest price target for Hoth Therapeutics (NASDAQ: HOTH) was reported by HC Wainwright & Co. on February 5, 2024. The analyst firm set a price target for $4.00 expecting HOTH to rise to within 12 months (a possible 168.46% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Hoth Therapeutics (NASDAQ: HOTH) was provided by HC Wainwright & Co., and Hoth Therapeutics initiated their buy rating.
There is no last upgrade for Hoth Therapeutics.
There is no last downgrade for Hoth Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hoth Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hoth Therapeutics was filed on February 5, 2024 so you should expect the next rating to be made available sometime around February 5, 2025.
While ratings are subjective and will change, the latest Hoth Therapeutics (HOTH) rating was a initiated with a price target of $0.00 to $4.00. The current price Hoth Therapeutics (HOTH) is trading at is $1.49, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.